Marka Kay News Today

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends. Institutional and Insider Ownership 87.6% of Sutro Biopharma shares […]

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Sutro Biopharma (NASDAQ:STRO – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk & Volatility Voyager Therapeutics has a beta of […]

C4 Therapeutics (NASDAQ:CCCC – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations. Institutional and Insider Ownership 80.3% of C4 Therapeutics shares […]

C4 Therapeutics (NASDAQ:CCCC – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Earnings & Valuation This table compares C4 Therapeutics and […]

In an open letter to the the Director of the Hoover Institute, the President, the Provost and the Board of Trustees, 90 Stanford faculty members call for a public accounting of Rupert Murdoch's appointment to the Hoover's Board of Overseers. They write, "we wonder what kind of signal his presence sends to our students, who we are training to seek the truth, and to our colleagues on the faculty, who are constantly held to the highest standards of honesty, truth and responsible scho...

Markets In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics (LOGC – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $6.10. According to TipRanks.com, Livshits is a top 100 analyst with an average return of 78.0% and a 71.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics. Logicbi...